BioSpace News Archive

Enanta Pharmaceuticals, Inc. announced that new data from its Phase 2a Human Challenge Study of EDP-938 is being presented as a late-breaker oral presentation today at IDWeek™ 2019 in Washington, D.C. EDP-938 is Enanta’s lead N-protein inhibitor being developed for the treatment of RSV infection.

Governor Gina Raimondo joined with University of Rhode Island President David Dooley to announce the second round of RI Innovation Campus projects that will catalyze academic research into new commercial products and businesses.

Frontage Laboratories, Inc., a contract research organization providing integrated, science-driven, product development services, is pleased to announce the expansion of their bioanalytical laboratories.

FUJIFILM Holdings Corporation is pleased to announce that it will sponsor the World Marketing Summit 2019 as a global partner.

Essity’s Interim report for the third quarter of 2019 will be published on October 25 at approximately 7:00 CET.

Dante Labs announced that it has begun installing Illumina next generation sequencing technology at its new European headquarters in Italy to make whole genome sequencing and whole exome sequencing available and accessible to individuals around the world through its global direct-to-consumer genomics platform.

AmacaThera Inc. is pleased to announce the closing of its US $3.6M seed financing round.

The market will accelerate at a CAGR of around 6.15% between 2019-2023

Applied DNA Sciences, Inc. announced that the Nasdaq Hearings Panel, has granted Applied DNA’s request for an extension through December 31, 2019, to comply with all applicable criteria for continued listing of the Company’s securities on The Nasdaq Capital Market, including the minimum $1.00 bid price and $2.5 million stockholders’ equity requirements.

Aroa Biosurgery, the Auckland-based privately held tissue-regeneration company, has this week presented positive outcomes of a new clinical study in Canada performed using its core wound product Endoform Natural®, which is being launched in the Canadian market along with Endoform Antimicrobial® in October 2019.